Nowadays, a primary question posed by pharmaceutical companies and investors, is how to create the optimal product portfolio for a Medical Cannabis investment.
Another question that arises is whether the companies need to make an investment in full spectrum medicines vs isolates.
The investment in either products’ mix and market requirements consequently imposes the need of understanding of what is involved and a different level of funding. So expert knowledge and sophisticated machinery are essential milestones that every investor should be checking at least at a high level.
To go a step further on this, let’s see what a full spectrum medicine refers to in order to create the optimal product portfolio of a Medical Cannabis investment.
Creating the optimal product portfolio for a Medical Cannabis investment
Cannabis dried flower can be processed and transformed into a variety of concentrates, tinctures, edibles, and other ones. The aim is to follow the same proper cultivation techniques & thereafter processes, as to harness all the crucial chemicals within the plant taking out account that when cannabinoids and terpenes exist together, this boosts the efficacy of the final medicine. This natural synergy of plant compounds, known as the entourage effect, is a well-researched phenomenon.
For the medical society and investors, the benefits of the entourage effect cannot be ignored. It is simply following nature’s wisdom. The drawback here is that is the expertise and the investment required in highly specialized machinery, to extract the correct ratio of cannabinoids and terpenes. Worth stating that these substances are incredibly volatile and can easily be destroyed, if not properly extracted through sophisticated stages of production and using highly specialized machinery.
On the other hand, market wise the alternative is the “Isolates” containing only one specific cannabinoid. Different isolates mixed together at certain concentrations by pharmaceutical companies, produce powerful pharmaceutical products. Correct extraction techniques are still required. So cost wise the investment is rather higher than full spectrum equipment since chromatography systems needed to extract isolates are still expensive (starting from € 0.6 million, if EU GMP certified).
A prudent answer in the question of how to create the optimal product portfolio for a Medical Cannabis investment, is selecting a full spectrum product’s portfolio to mitigate funds requirements but being proactive in terms of a facility design, as to be capable to enroll isolates in the production line as market moves forward fast.